News - OBI Pharma 台灣浩鼎

2019.Feb.12

未分類

Corporate

New Scientific Research provides link between Globo-series glycosphingolipids (GSLs) antigens and tumor survival in Breast Cancer

2019.Jan.09

未分類

Corporate

OBI Pharma, Inc. to Present at the J.P. Morgan Healthcare Conference

2018.Nov.21

未分類

Corporate

OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer

2018.Sep.19

未分類

Corporate

OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)

2018.Jul.08

未分類

Corporate

OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Hepatocellular Carcinoma (HCC)

2018.Apr.19

未分類

Corporate

OBI Pharma Announces FDA Clearance of OBI-3424 IND Application for A Phase I/II Study Targeting AKR1C3 Solid Tumors

2018.Jan.17

未分類

Corporate

OBI Pharma Announces FDA Clearance Of IND Application For A Phase 1 Study Of A Monoclonal Antibody Cancer Immunotherapy (OBI-888)

2017.Dec.22

未分類

Corporate

OBI Pharma announces participation at the 36th J.P. Morgan Annual Healthcare Conference in San Francisco from January 8-10, 2018.

2017.Oct.30

未分類

Corporate

OBI Pharma announces OBI-3424 results from the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2017.Oct.24

未分類

Corporate

OBI Pharma Announces Presentation on OBI-3424 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Announcements

Latest announcements

Events

Latest events